WIA
RLAY icon

Wetzel Investment Advisors’s Relay Therapeutics RLAY Stock Holding History

Wetzel Investment Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-500
Closed -$4.15K – 727
2024
Q2 		$4.15K Hold
500
– – ﹤0.01% 616
2024
Q1 		$3.06K Hold
500
– – ﹤0.01% 768
2023
Q4 		$6K Buy
+500
New +$4.22K ﹤0.01% 654

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Wetzel Investment Advisors's RLAY Position: Q3 2024 in Review

Wetzel Investment Advisors sold out of Relay Therapeutics (RLAY) in Q3 2024, closing a stake of 500 shares — an estimated $4.15K sold.

Wetzel Investment Advisors first reported a position in RLAY in Q4 2023 and held it in 3 quarters. The position peaked at $6K in Q4 2023. 195 funds tracked by Wall St. Rank hold RLAY as of Q3 2024.

  • Wetzel Investment Advisors reported no remaining Relay Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Wetzel Investment Advisors sold 500 Relay Therapeutics shares in Q3 2024, an estimated $4.15K.
  • Wetzel Investment Advisors first reported a position in Relay Therapeutics in Q4 2023 and held it in 3 quarters.
  • Wetzel Investment Advisors's Relay Therapeutics position peaked at $6K in Q4 2023.
  • 195 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2024.

Based on Wetzel Investment Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.